What is liraglutide? Structure, research and status

Liraglutide is a modified GLP-1 peptide developed by Novo Nordisk and the active ingredient in the FDA-approved medicines Victoza, Saxenda and Xultophy.

Complete guide10 min read

Key takeaway

Liraglutide shares 97% of its amino acid sequence with human GLP-1(7-37) and carries a C-16 fatty acid that binds plasma proteins. Its labeled uses are type 2 diabetes, cardiovascular risk reduction in some adults with diabetes, and weight management. In the LEADER trial of 9,340 adults, fewer major cardiovascular events occurred with liraglutide than with placebo. The Victoza and Saxenda labels carry a boxed warning about thyroid C-cell tumors seen in rodents.

At a glance

Article typeComplete guide
On Liraglutide1 more article
Regulatory statusFDA-approved“Liraglutide is FDA-approved as the active ingredient in Victoza, Saxenda and Xultophy.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited6 in this article · 10 across 2 articles on Liraglutide
Related productsIncretin analogs

Liraglutide is a lab-made version of the gut hormone GLP-1 with one amino acid swapped and a fatty acid attached. Those changes turn a hormone that lasts about two minutes in blood into one with a half-life of about 13 hours. FDA first approved it as Victoza in 2010, and the first generics followed in 2024 and 2025.

Quick answer: Liraglutide is a GLP-1 receptor agonist peptide. Liraglutide is FDA-approved as the active ingredient in Victoza, Saxenda and Xultophy. Generics referencing Victoza and Saxenda were approved in December 2024 and August 2025. Approval covers those labeled products, not research material sold under the same name.

Vitrapep does not sell liraglutide; this page is a reference summary of published research and regulatory information.

What is liraglutide and how is it built?

Liraglutide is a synthetic analog of glucagon-like peptide-1, a hormone the intestine releases after meals (see what GLP-1 is).

The Victoza label describes the molecule. Its peptide precursor is made by recombinant DNA expression in the yeast Saccharomyces cerevisiae. Arginine replaces lysine at position 34, leaving a 97% match to native GLP-1. A C-16 fatty acid, palmitic acid, is attached through a glutamic acid spacer to the lysine at position 26 [1].

The fatty acid is the central design choice. Novo Nordisk scientists Lotte Bjerre Knudsen and Jesper Lau describe reversible albumin binding as the strategy used to extend liraglutide's action. Fatty acid and linker combinations were chosen to maximize albumin binding while keeping receptor potency [4]. Novo Nordisk later used the same approach for semaglutide, covered in the semaglutide complete guide.

Table 1

What is liraglutide and how is it built

PropertyLiraglutide
ClassAcylated GLP-1 receptor agonist; a peptide [1]
Match to human GLP-1(7-37)97% amino acid sequence homology [1]
Changes from native GLP-1Arginine for lysine at position 34; C-16 fatty acid with a glutamic acid spacer on lysine 26 [1]
Molecular formulaC172H265N43O51 (PubChem CID 16134956) [3]
Molecular weight3751 g/mol in PubChem; 3751.2 daltons on the label [1], [3]
Plasma protein bindingMore than 98% [1]
Elimination half-lifeAbout 13 hours, versus 1.5 to 2 minutes for native GLP-1(7-37) [1]
US brands and approval yearsVictoza (2010), Saxenda (2014), Xultophy with insulin degludec (2016) [13]
First US genericsDecember 23, 2024 (references Victoza); August 27, 2025 (references Saxenda) [10], [11]
First EU authorizationVictoza, June 30, 2009 (EMA)

How does liraglutide work?

Liraglutide activates the GLP-1 receptor, the same receptor the natural hormone uses. On pancreatic beta cells, receptor activation raises cyclic AMP, which leads to insulin release when glucose is elevated. Insulin secretion subsides as blood glucose falls toward normal. Liraglutide also lowers glucagon secretion in a glucose-dependent way and delays gastric emptying [1].

Duration is the main difference from native GLP-1. The enzymes DPP-4 and neutral endopeptidases clear GLP-1(7-37) within minutes. The label says liraglutide resists both enzymes. It credits self-association, plasma protein binding and enzyme stability for the longer half-life [1].

The weight effect involves the brain. The Saxenda label says GLP-1 receptors are present in brain areas that regulate appetite [2]. A 2014 study by Secher and colleagues tracked fluorescently labeled liraglutide in mice. It bound neurons in the arcuate nucleus of the hypothalamus, and binding required the GLP-1 receptor. In rats, weight reduction did not depend on GLP-1 receptors in the vagus nerve, area postrema or paraventricular nucleus [5]. These are animal findings, not human data.

What is liraglutide approved for?

Approved uses come from section 1 of each product label. Other approved peptides appear in Vitrapep's list of FDA-approved peptide medicines.

Victoza is approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes. This covers adults and pediatric patients aged 10 and older. It is also approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [1]. FDA added that indication in August 2017, based on LEADER (approval letter). The pediatric age range was expanded in June 2019 (approval letter).

Saxenda is approved, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term. It covers adults and pediatric patients aged 12 and older with body weight greater than 60 kg and obesity. It also covers adults with overweight and at least one weight-related condition. Safety and effectiveness in pediatric patients with type 2 diabetes have not been established [2].

Xultophy combines liraglutide with insulin degludec. FDA lists it among approved GLP-1 receptor agonist medicines, with a 2016 approval year [13].

What did the key liraglutide trials show?

LEADER (NCT01179048) added liraglutide or placebo to standard care in adults with type 2 diabetes and high cardiovascular risk. Its primary outcome combined cardiovascular death, nonfatal heart attack and nonfatal stroke. Cardiovascular death occurred in 4.7% versus 6.0%, and death from any cause in 8.2% versus 9.6% [6].

SCALE Obesity and Prediabetes (NCT01272219) enrolled 3,731 adults without type 2 diabetes who had obesity, or overweight with dyslipidemia or hypertension. Both groups received lifestyle counseling. More than 10% of body weight was lost by 33.1% versus 10.6%. Serious adverse events occurred in 6.2% versus 5.0% [7]. The Saxenda label, which handles missing data differently, reports mean weight changes of 7.4% versus 3.0% [2].

Ellipse (NCT01541215) enrolled 134 patients aged 10 to under 17 with type 2 diabetes, all on metformin. After the 26-week double-blind period, an open-label extension ran to 52 weeks. The HbA1c difference grew to 1.30 percentage points by week 52 [8].

Kelly and colleagues (NCT02918279) studied 251 adolescents aged 12 to under 18 with obesity and a poor response to lifestyle therapy alone. A BMI reduction of at least 5% occurred in 43.3% versus 18.7% [9].

Table 2

What did the key liraglutide trials show

TrialPopulation and sizeDesign and lengthPrimary result
LEADER, 2016 [6]9,340 adults with type 2 diabetes and high cardiovascular riskDouble-blind; median follow-up 3.8 yearsMajor cardiovascular events 13.0% vs 14.9%; hazard ratio 0.87 (95% CI, 0.78 to 0.97)
SCALE Obesity and Prediabetes, 2015 [7]3,731 adults with obesity or overweight, without diabetesDouble-blind; 56 weeksMean weight loss 8.4 kg vs 2.8 kg; at least 5% loss in 63.2% vs 27.1%
Ellipse, 2019 [8]134 patients aged 10 to under 17 with type 2 diabetesDouble-blind for 26 weeks, then open-labelHbA1c fell 0.64 points vs rose 0.42; difference 1.06 points at week 26
Kelly et al., 2020 [9]251 adolescents aged 12 to under 18 with obesityDouble-blind; 56 weeks plus 26-week follow-upBMI standard-deviation score 0.22 lower than placebo at week 56

All four are human randomized, placebo-controlled trials described in the labels. Head-to-head trials against semaglutide are covered in Vitrapep's liraglutide vs semaglutide comparison.

What side effects do the liraglutide labels list?

Boxed warning. Liraglutide causes thyroid C-cell tumors in rats and mice at clinically relevant exposures. It is unknown whether it causes such tumors in humans, including medullary thyroid carcinoma (MTC). It is contraindicated with a personal or family history of MTC or with MEN 2. Postmarketing MTC cases have been reported, but the data cannot establish or exclude a causal link [1].

Common reactions. Victoza's most common reactions, each in at least 5% of patients, are nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation. In pooled adult placebo-controlled trials, nausea occurred in 18% to 20% on liraglutide versus 5% on placebo [1]. In the Saxenda adult trials, 9.8% versus 4.3% stopped because of adverse reactions [2].

Table 3

What side effects do the liraglutide labels list

Adverse reactionSaxenda adults, % (N=3,384)Placebo, % (N=1,941)
Nausea39.313.8
Diarrhea20.99.9
Constipation19.48.5
Vomiting15.73.9
Injection site reaction13.910.5
Dyspepsia9.62.7
Increased lipase5.32.2

Source: Saxenda label, Table 2 [2]. In the adolescent obesity trial, gastrointestinal events occurred in 64.8% versus 36.5% [9].

Warnings and precautions. The labels warn of acute pancreatitis, including fatal hemorrhagic or necrotizing cases seen with GLP-1 receptor agonists. In LEADER, acute gallbladder events occurred in 3.1% on liraglutide versus 1.9% on placebo [1]. Other warnings cover hypoglycemia with insulin or insulin secretagogues, acute kidney injury from volume depletion and severe gastrointestinal reactions. Serious hypersensitivity and pulmonary aspiration during general anesthesia or deep sedation are also listed [1]. Saxenda adds a heart rate warning: mean resting heart rate rose 2 to 3 beats per minute versus placebo in adults [2].

What changed for liraglutide labels in 2026?

On January 13, 2026, FDA asked companies to remove the suicidal behavior and ideation warning from the Saxenda, Wegovy and Zepbound labels. A meta-analysis of 91 placebo-controlled trials with 107,910 patients showed no increased risk [12]. The Saxenda label lists the warning as removed in February 2026 [2].

On November 9, 2026, FDA said all GLP-1 receptor agonist labels must warn of a potential increased risk of NAION. NAION is a rare optic nerve condition. Its list includes Victoza, Saxenda and Xultophy. Pooled trials gave a rate of 6.4 per 100,000 person-years with GLP-1 receptor agonists versus 3.8 with comparators [13]. See Vitrapep's summary of FDA's GLP-1 eye-risk warning. The DailyMed labels for Victoza and Saxenda did not yet show it on November 18, 2026 [1], [2].

What is the regulatory status of liraglutide?

Generics. FDA approved the first generic referencing Victoza on December 23, 2024, and noted that liraglutide injection was then in shortage [10]. Teva's generic referencing Saxenda, the first for that product, followed on August 27, 2025 [11].

Shortage. On November 18, 2026, FDA's drug shortage database still listed liraglutide injection as in shortage, first posted July 18, 2023. Novo Nordisk's entry reports limited Victoza supply from shipping delays. It says Saxenda will be available until discontinuation in January 2027.

Compounding. On April 30, 2026, FDA proposed leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list (FDA announcement). That list names bulk substances outsourcing facilities may use. FDA said it found no clinical need for compounding these drugs from bulk substances. The Federal Register notice appeared on May 1, 2026 [14].

Research-labeled products. FDA's page on unapproved GLP-1 drugs describes warnings to sellers of products falsely labeled "for research purposes." That page names semaglutide and tirzepatide, not liraglutide. A research-use-only label does not make a product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.

Other countries and sport. The European Union authorized Saxenda on March 23, 2015. Its EU indication includes children aged 6 to under 12 with obesity, a group the US label does not cover. The WADA 2026 Prohibited List does not name liraglutide or GLP-1 receptor agonists.

What is still unknown about liraglutide?

The human relevance of the rodent thyroid tumors is undetermined [1]. In 2019, Knudsen and Lau wrote that the cardiovascular mechanism was still being explored [4]. FDA found no NAION mechanism in animal data [13]. The pediatric trials ran about one year [8], [9].

Frequently asked questions

Is liraglutide a peptide?

Yes. It is a modified version of the GLP-1(7-37) peptide with a fatty acid attached.

Is liraglutide the same as Victoza or Saxenda?

Liraglutide is the active ingredient. Victoza, Saxenda and Xultophy are separate products with different labels and approved uses.

How is liraglutide different from semaglutide?

Both are acylated GLP-1 analogs from Novo Nordisk. Semaglutide has a longer fatty acid side chain and an amino acid change at position 8. The GLP-1 class overview covers the wider class.

Is there a generic version of liraglutide?

Yes. FDA approved the first generic referencing Victoza in December 2024 and the first referencing Saxenda in August 2025.

Does liraglutide have a boxed warning?

Yes. The Victoza and Saxenda labels warn about thyroid C-cell tumors in rats and mice. Whether liraglutide causes them in humans is unknown.

Is research-grade liraglutide FDA-approved?

No. FDA approval applies to labeled products made under approved applications. Material sold for laboratory research is not an approved medicine.

What to know now

  • Liraglutide is a 97% match to human GLP-1(7-37), with a fatty acid that extends its half-life to about 13 hours.
  • Approved uses come from the Victoza, Saxenda and Xultophy labels, not from the molecule name.
  • LEADER showed fewer major cardiovascular events than placebo; SCALE showed greater mean weight loss than placebo.
  • In 2026, the Saxenda suicidality warning was removed at FDA's request, and FDA required a class-wide NAION warning.

What we’re watching

  • FDA's final decision on leaving liraglutide off the 503B bulks list.
  • NAION warning text appearing on the Victoza, Saxenda and Xultophy labels.
  • The planned Saxenda discontinuation in January 2027 and the liraglutide shortage listing.

Everything on Liraglutide

More for endocrine & metabolism

All 41 compounds for endocrine & metabolism

Sources: U.S. National Library of Medicine 2025; U.S. National Library of Medicine 2026; National Center for Biotechnology Information 2026; Knudsen 2019, Frontiers in Endocrinology, 10; Secher 2014, Journal of Clinical Investigation, 124; Marso 2016, New England Journal of Medicine, 375; Pi-Sunyer 2015, New England Journal of Medicine, 373; Tamborlane 2019, New England Journal of Medicine, 381; Kelly 2020, New England Journal of Medicine, 382; U.S. Food and Drug Administration 2024; U.S. Food and Drug Administration 2025; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026; Food and Drug Administration 2026, Federal Register. All 14 citations

Back to the research library

References

  1. U.S. National Library of Medicine. (2025). Victoza (liraglutide) injection: prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
  2. U.S. National Library of Medicine. (2026). Saxenda (liraglutide) injection: prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16134956, liraglutide. https://pubchem.ncbi.nlm.nih.gov/compound/16134956
  4. Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155
  5. Secher, A., Jelsing, J., Baquero, A. F., et al. (2014). The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation, 124(10), 4473-4488. https://doi.org/10.1172/JCI75276
  6. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322. https://doi.org/10.1056/NEJMoa1603827
  7. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892
  8. Tamborlane, W. V., Barrientos-Pérez, M., Fainberg, U., et al. (2019). Liraglutide in children and adolescents with type 2 diabetes. New England Journal of Medicine, 381(7), 637-646. https://doi.org/10.1056/NEJMoa1903822
  9. Kelly, A. S., Auerbach, P., Barrientos-Perez, M., et al. (2020). A randomized, controlled trial of liraglutide for adolescents with obesity. New England Journal of Medicine, 382(22), 2117-2128. https://doi.org/10.1056/NEJMoa1916038
  10. U.S. Food and Drug Administration. (2024). FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes
  11. U.S. Food and Drug Administration. (2025). 2025 first generic drug approvals. https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals
  12. U.S. Food and Drug Administration. (2026). FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
  13. U.S. Food and Drug Administration. (2026). FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  14. Food and Drug Administration. (2026). List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act. Federal Register, FR Doc. 2026-08552. https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal